Cantor Fitzgerald raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $10 from $8 and keeps an Overweight rating on the shares. The firm updated its model following the Q4 earnings report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals: Advancing Gene Therapy Pipeline and High-Confidence KRESLADI Approval Drive Buy Rating
- Balanced View on RCKT: Clinical Progress Offsetting Execution and Regulatory Risks Supports Hold Rating
- Rocket Pharmaceuticals reports Q4 EPS (38c), consensus (42c)
- Rocket Pharmaceuticals price target lowered to $5 from $7 at Morgan Stanley